A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
GlioblastomaGlioblastoma Multiforme
Interventions
DRUG

TRC105

10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle

DRUG

Bevacizumab

IV

Trial Locations (4)

43210

Ohio State University, Columbus

44106

University Hospitals of Cleveland, Cleveland

44195

Cleveland Clinic, Cleveland

45267

University of Cincinnati, Cincinnati

All Listed Sponsors
collaborator

The Cleveland Clinic

OTHER

collaborator

Case Comprehensive Cancer Center

OTHER

lead

Tracon Pharmaceuticals Inc.

INDUSTRY

NCT01564914 - A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma | Biotech Hunter | Biotech Hunter